In the TIL analysis using samples before NIVO, high group showed shorter PFS/OS compared with low group divided by CD11b+CTLA4+ (median [m] PFS 27 vs 67 days, HR = 2.37, p = 0.001/ mOS 103 vs 228 days, HR = 2.02, p = 0.013), and CD11b+LAG3+ (mPFS 35 vs 60 days, HR = 2.23, p = 0.003/ mOS 104 vs 228 days, HR = 1.71, p = 0.070), showing relatively stronger association compared to CD11b+PD1+.... In the PBC analysis using samples before NIVO, high group showed shorter PFS/OS compared with low group divided by CD11b+CTLA4+ (mPFS 49.5 vs 99 days, HR = 1.76, p = 0.029/ mOS 167 vs 393 days, HR = 1.63, p = 0.101), and CD11b+LAG3+ (mPFS 46 vs 60.5 days, HR = 1.70, p = 0.017/ OS median 178 vs 185 days, HR = 1.19, p = 0.483)....High proportions of CTLA4+ and LAG3+ myeloid subsets in TIL and PBC before treatment were associated with poor prognosis after NIVO in AGC patients...